EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment‐Resistant Depression

Stephanie Njau, Artemis Zavaliangos-Petropulu iD, Shantanu Joshi, John Brooks, Joseph O'Neill, Woods P Roger, Viviane Norris, Randall T Espinoza, Katherine L Narr

Journal of Neuroscience Research · 2026

DOI: 10.1002/jnr.70102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroscience Research, 2026. Verfasst von Stephanie Njau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ahmanson-Lovelace Brain Mapping Center, Geffen School of Medicine at the University of California, Los Angeles, Los Angeles,…. Hauptthemen laut MEDLINE: Ketamine, Glutamic Acid, Depressive Disorder, Treatment-Resistant, gamma-Aminobutyric Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ketamine has emerged as a highly effective intervention for treatment‐resistant depression (TRD). Though it acts as a non‐competitive antagonist of excitatory N‐methyl‐D‐aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ‐aminobutyric acid (GABA)‐ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate and GABA neurotransmission and the clinical benefits of ketamine, we used proton magnetic resonance spectroscopy ( 1 H‐MRS) to measure both glutamate and GABA levels in the dorsal anterior cingulate cortex (dACC) in 60 participants with TRD before (~within 1 week), and 24 h after a 40‐min intravenous infusion with 0.5 mg/kg of racemic ( R,S )‐ketamine. The 17‐item Hamilton Depression Rating Scale (HDRS 17 ) was used as the primary measure of clinical improvement, and a 50% or greater improvement in HDRS 17 ratings was used to define treatment responders. Ketamine increased mean dACC glutamate levels in responders only 24 h after treatment ( n = 25, p = 0.01). Further, lower glutamate levels at baseline predicted greater improvements in HDRS 17 scores at 24 h post treatment ( p < 0.0001). However, GABA levels remained stable after treatment irrespective of response status ( p = 0.90). Metabolites associated with neuronal integrity (tNAA), metabolic function (tCr), and membrane turnover (tCho), which may serve as complementary biological evidence of ketamine‐induced plasticity, also increased with treatment (all p < 0.01). Results provide evidence of sustained enhancements of neurotransmission or other glutamate‐related metabolic effects following subanesthetic ketamine in responders and a potential role of ACC glutamate levels as a biomarker of responsivity to ketamine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineGlutamic AcidDepressive Disorder, Treatment-Resistantgamma-Aminobutyric AcidGyrus CinguliAntidepressive AgentsHumansMaleFemaleAdultMiddle AgedMagnetic Resonance SpectroscopyProton Magnetic Resonance SpectroscopyExcitatory Amino Acid Antagonists

Stichwörter der Autor:innen

depressionketamineproton magnetic resonance spectroscopy

Substanzen

KetamineGlutamic Acidgamma-Aminobutyric AcidAntidepressive AgentsExcitatory Amino Acid Antagonists

Autor:innen und Institutionen

  • Department of Neurology, Ahmanson-Lovelace Brain Mapping Center, Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, U…

ORCID-Profile: Artemis Zavaliangos-Petropulu

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Njau, S., Zavaliangos-Petropulu, A., Joshi, S., Brooks, J., O'Neill, J., Roger, W. P., Norris, V., Espinoza, R. T., & Narr, K. L. (2026). Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment‐Resistant Depression. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.70102

Vancouver

Njau S, Zavaliangos-Petropulu A, Joshi S, Brooks J, O'Neill J, Roger WP, et al. Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment‐Resistant Depression. Journal of Neuroscience Research. 2026. doi:10.1002/jnr.70102

BibTeX
@article{Njau2026,
  author = {Njau, Stephanie and Zavaliangos-Petropulu, Artemis and Joshi, Shantanu and Brooks, John and O'Neill, Joseph and Roger, Woods P and Norris, Viviane and Espinoza, Randall T and Narr, Katherine L},
  title = {Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment‐Resistant Depression},
  journal = {Journal of Neuroscience Research},
  year = {2026},
  doi = {10.1002/jnr.70102}
}
Kostenlos starten →